title: [Non Hodgkin's and Hodgkin's lymphomas and HIV: frequency, outcome and immune response under HAART; Clermont-Ferrand University Hospital, 1991-2003].
abstract: OBJECTIVE
  The authors had for aim to identify cases of non Hodgkin's (NHL) and Hodgkin's (HL) lymphomas in HIV1-infected patients to assess 1) their incidence, before and after 1996, 2) the clinical features and outcome under treatment together with the survival rate of the patients, 3) the immune reconstitution of lymphoma-free patients under HAART.
  
  
  METHODS
  A retrospective study was made of HIV1-infected patients managed at the Clermont-Ferrand University Hospital from 1991 to 2003 for the diagnosis and treatment of HIV1-related lymphomas.
  
  
  RESULTS
  Forty-one patients were included: 35 NHL and 6 HL giving a cumulative incidence rate estimate from 2.4% between 1991 and 1996 to 3.4% between 1997 and 2003 while other opportunistic diseases were decreasing. A high proportion of aggressive and disseminated disease was observed among NHL cases. Complete remission was achieved in 17 (49%) and 5 (83%) NHL and HL cases respectively. The mean survival was 109+/-54 months and was correlated with CD4 cell count at lymphoma diagnosis (univariate analysis). Among responding patients, 5 died: 3 from opportunistic infections, 1 commited suicide, and 1 from hepatic carcinoma. For responding patients, the mean increase of CD4 cell count under HAART was 58/mm3 over a 2 year-period and 192/mm3 over a 5 year-period of follow-up.
  
  
  CONCLUSIONS
  The incidence of lymphomas in HIV-infected patients has not decreased since the introduction of HAART. The immune status assessed by CD4 cell count on diagnosis is correlated with survival. Immune restoration in lymphoma-free patients under HAART is poor.
authors.affiliation: Service des maladies infectieuses et tropicales, CHU de Clermont-Ferrand, BP 69, 63000 Clermont-Ferrand, France. cjacomet@chu-clermontferrand.fr
authors.forename: C
authors.initials: C
authors.lastname: Jacomet
authors.forename: O
authors.initials: O
authors.lastname: Lesens
authors.forename: B
authors.initials: B
authors.lastname: Villemagne
authors.forename: C
authors.initials: C
authors.lastname: Darcha
authors.forename: O
authors.initials: O
authors.lastname: Tournilhac
authors.forename: C
authors.initials: C
authors.lastname: Henquell
authors.forename: L
authors.initials: L
authors.lastname: Cormerais
authors.forename: F
authors.initials: F
authors.lastname: Gourdon
authors.forename: H
authors.initials: H
authors.lastname: Peigue-Lafeuille
authors.forename: P
authors.initials: P
authors.lastname: Travade
authors.forename: J
authors.initials: J
authors.lastname: Beytout
authors.forename: H
authors.initials: H
authors.lastname: Laurichesse
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000453:epidemiology; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D015331:Cohort Studies; D005260:Female; D005602:France / Q000453:epidemiology; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology; D015497:HIV-1; D006689:Hodgkin Disease / Q000188:drug therapy / Q000453:epidemiology*; D006785:Hospitals, University / Q000706:statistics & numerical data; D006801:Humans; D015994:Incidence; D016483:Lymphoma, AIDS-Related / Q000188:drug therapy / Q000453:epidemiology*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000453:epidemiology*; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome